BRAF is an oncogene that is commonly mutated in both melanomas and papillary thyroid
carcinomas (PTCs). Usually, mutations in the codons 600 or 601 lead to constitutive activity …

Objective The somatic point mutation in the BRAF gene, which results in a valine-to-
glutamate substitution at residue 600 (BRAFV600E), is an ideal hallmark of papillary thyroid …

A BRAF somatic mutation at residue 600 of the BRAF protein (BRAFV600E) is highly
prevalent in papillary thyroid carcinomas (PTC). This mutation occurs in approximately …

A common mutation in the BRAF gene, comprising the T1799A nucleotide transversion,
which leads to the V600E amino acid substitution in the BRAF protein, has been observed in …

The most common genetic alteration identified in papillary thyroid cancer (PTC) encodes a
valine to glutamic acid change at position 600 (V600E) in the BRAF proto‑oncoprotein. The …

Background: A single hotspot mutation at nucleotide 1799 of the BRAF gene has been
identified as the most common genetic event in papillary thyroid carcinoma (PTC), with a …

An activating mutation in the BRAF gene is the most common genetic alteration in papillary
thyroid carcinomas (PTCs). The mutation in PTCs is almost a c. 1799T> A transversion …

Background BRAF mutations occur in approximately 8% of all human cancers and approach
50% in melanoma and papillary carcinoma of thyroid. These mutations provide potentially …

Activating mutations of the BRAF gene are the most common genetic alterations in papillary
thyroid carcinomas (PTCs) and the T1799A transversion, resulting in BRAF V600E …

BRAF, a cytoplasmic serine–threonine protein kinase, plays a critical role in cell signaling as
an activator within the mitogen-activated protein kinase (MAPK) pathway. The most common …